Exact Sciences Reports Q1 Loss

(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million ...

First quarter highlights Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of ...

Net loss was $38 million, or $0.21 per basic and diluted share, a reduction of $39 million, or $0.21 per basic and diluted share; Adjusted ...

Revenue: Reported $638 million, a 6% increase year-over-year, falling short of the estimated $700.15 million. · Net Loss: Widened to $110 million ...

Exact Sciences reported a third-quarter loss of 21 cents a share on revenue of $708.7 million. Analysts were expecting a loss of 21 cents a ...

Exact Sciences Corp. on Wednesday reported a first-quarter loss that matched analysts' expectations and revenue that beat expectations. The ...

Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, ...

Exact Sciences Corporation EXAS reported a net loss of 50 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate.

Madison's Exact Sciences Corp. reported a first-quarter loss of $110.2 million Wednesday, according to the Wisconsin State Journal.

Exact Sciences reports a quarterly loss of 60 cents per share, missing analyst estimates for a loss of 48 cents per share. Exact Sciences Corp.

Also bearishly, Exact Sciences reported a wider-than-expected loss at 60 cents per share. That grew from a year-earlier loss of 42 cents and ...

Exact Sciences to Participate in November Investor Conference. November 01, 2024. View All Releases. Latest Quarterly Results. Q32024.

(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated ...

Exact Sciences ( EXAS Quick Quote EXAS - Free Report) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus ...

EXACT Sciences will be reporting Q1 earnings on May 8.Wall Street analysts expect EXACT Sciences will report losses per share of $0.475.

For the three and twelve months ended December 31, 2022, this represents the loss on the sale of $13.2 million, $1.8 million in one-time ...

NEW YORK(GenomeWeb) – Exact Sciences today reported $4.3 million in revenues for the first quarter, beating the consensus Wall Street estimate ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20.